RocketTickers

Krystal Biotech Announces Positive Results from Phase 2 Clinical

Long
NASDAQ:KRYS   Krystal Biotech, Inc
KRYS: Krystal Biotech , Inc.
2019-06-24 08:00:00
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103 - GlobeNewswire

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.